alt

52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012)

September 9-12, 2012, San Francisco

ICAAC 2012: Experimental Nitroimidazole TBA-354 Shows Promise against Tuberculosis in Early Studies

The experimental nitroimidazole TBA-354, under investigation by the TB Alliance, showed potent activity against Mycobacterium tuberculosis in vitro and in animal studies, according to a presentation this week at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) in San Francisco. alt

Read more:

ICAAC 2012: Atazanavir Linked to Kidney Stones in People with HIV

HIVandHepatitis.com coverage of the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, September 9-12, 2012.

Topics highlighted this year include experimental antiretroviral drugs, complications related to HIV and its treatment, recent developments in hepatitis C therapy, cancer caused by HPV, influenza, tuberculosis, and STDs.

Full listing by topic

HIVandHepatitis.com ICAAC 2012 conference section

alt

ICAAC Meeting Underway in San Francisco -- HIV, HCV, HPV, Flu, and More

The 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy -- better known as ICAAC -- opened Sunday, September 9, at San Francisco's Moscone Center.alt

Read more:

ICAAC 2012: HIV+ People Have Heart Attacks Younger, Receive Later Care, Die More Often

People with HIV had heart attacks at a younger age than HIV negative individuals and were about 50% more likely to die after an acute myocardial infarction, according to a study presented this week at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) in San Francisco. A related analysis found that HIV positive people received coronary catheterization at a later stage, after they had more advanced heart damage.alt

Read more:

Unboosted Atazanavir Maintains Long-term HIV Suppression

HIV patients with suppressed viral load who switched from ritonavir-boosted atazanavir (Reyataz) to unboosted atazanavir in a combination antiretroviral regimen were able to maintain undetectable HIV RNA over 120 weeks with a low risk of viral rebound and fewer side effects, according to the latest findings from the ARIES trial presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) last week in Boston.

Read more: